Jilin Kemike Chemical Co., Ltd., located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a national high-tech enterprise specializing in the research, development, production, and sales of high-end organofluorine chemicals, fluorinated pharmaceutical intermediates, and specialty functional materials. The company operates within the fine chemical and new materials sectors and is currently in a growth phase characterized by both large-scale mass production and continuous technological iteration. Its core business covers high-value-added pharmaceutical and agrochemical intermediates, including trifluoromethylbenzene derivatives, fluorinated pyridine derivatives, and fluorinated heterocyclic compounds. Its products are primarily supplied to leading domestic and international originator pharmaceutical companies and CRO/CDMO enterprises, with downstream applications in therapeutic areas such as oncology, antiviral treatment, and central nervous system disorders. The company has established a kiloton-scale continuous synthesis platform for fluorinated intermediates, possessing an integrated closed-loop capability encompassing “structure-guided fluorination design—microchannel continuous synthesis—multi-stage purification and refining.” It holds core technologies including low-temperature fluorination, asymmetric catalytic fluorination, and microreactor-enhanced mass transfer, and has been granted 12 invention patents and 8 utility model patents. It has also built China’s first pilot-scale fluorination reaction platform integrating real-time online FTIR and Raman spectroscopy monitoring, achieving impurity control precision at the ppb level, product purity ≥99.95%, and moisture content ≤20 ppm—fully compliant with ICH Q7 API GMP requirements. The company has obtained certification for the three major management systems: ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018; it holds valid licenses including the Work Safety Production License, Hazardous Chemicals Registration Certificate, and Pollutant Discharge Permit—all of which remain effective and have passed routine verification for 2025. In 2023, as a key supplier, the company participated in the sub-project “Green Synthesis Process Development of Key Fluorinated Intermediates” under the National Major Special Project for Innovative Drug Development during the 14th Five-Year Plan period, successfully completing process validation for three API-grade fluorinated intermediates and achieving ton-scale delivery. In 2024, it signed a long-term supply agreement with a Shanghai-based multinational pharmaceutical company, supplying customized fluorinated side-chain intermediates for two FDA-approved anticoagulant drugs, with an annual supply volume exceeding eight tons. Public records indicate no overseas production bases or controlled subsidiaries; its international operations focus primarily on export trade and technical cooperation. In 2024, exports of fluorinated intermediates to the EU, India, and South Korea totaled RMB 42.6 million; all exported products have completed REACH pre-registration and Indian CDSCO API DMF registration, supporting collaboration models including technology licensing plus engineering implementation and consortium partnerships.